|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:RPN2-MYL9 (FusionGDB2 ID:76731) |
Fusion Gene Summary for RPN2-MYL9 |
Fusion gene summary |
Fusion gene information | Fusion gene name: RPN2-MYL9 | Fusion gene ID: 76731 | Hgene | Tgene | Gene symbol | RPN2 | MYL9 | Gene ID | 6185 | 10398 |
Gene name | ribophorin II | myosin light chain 9 | |
Synonyms | RIBIIR|RPN-II|RPNII|SWP1 | LC20|MLC-2C|MLC2|MRLC1|MYRL2 | |
Cytomap | 20q11.23 | 20q11.23 | |
Type of gene | protein-coding | protein-coding | |
Description | dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2dolichyl-diphosphooligosaccharide--protein glycosyltransferase 63 kDa subunitoligosaccharyltransferase complex subunit (non-catalytic)ribophorin-2 | myosin regulatory light polypeptide 920 kDa myosin light chainepididymis secretory sperm binding proteinmyosin RLCmyosin regulatory light chain 1myosin regulatory light chain 2, smooth muscle isoformmyosin regulatory light chain 9myosin regulatory | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | . | P24844 | |
Ensembl transtripts involved in fusion gene | ENST00000237530, ENST00000373622, ENST00000470352, | ENST00000279022, ENST00000346786, | |
Fusion gene scores | * DoF score | 15 X 12 X 8=1440 | 5 X 4 X 4=80 |
# samples | 17 | 5 | |
** MAII score | log2(17/1440*10)=-3.08246216019197 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(5/80*10)=-0.678071905112638 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: RPN2 [Title/Abstract] AND MYL9 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | RPN2(35842268)-MYL9(35177480), # samples:2 | ||
Anticipated loss of major functional domain due to fusion event. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Fusion gene breakpoints across RPN2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across MYL9 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | LUSC | TCGA-66-2793-01A | RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177480 | + |
ChimerDB4 | LUSC | TCGA-66-2793 | RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177480 | + |
Top |
Fusion Gene ORF analysis for RPN2-MYL9 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
In-frame | ENST00000237530 | ENST00000279022 | RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177480 | + |
In-frame | ENST00000237530 | ENST00000346786 | RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177480 | + |
In-frame | ENST00000373622 | ENST00000279022 | RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177480 | + |
In-frame | ENST00000373622 | ENST00000346786 | RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177480 | + |
intron-3CDS | ENST00000470352 | ENST00000279022 | RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177480 | + |
intron-3CDS | ENST00000470352 | ENST00000346786 | RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177480 | + |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000237530 | RPN2 | chr20 | 35842268 | + | ENST00000279022 | MYL9 | chr20 | 35177480 | + | 2152 | 1403 | 209 | 1744 | 511 |
ENST00000237530 | RPN2 | chr20 | 35842268 | + | ENST00000346786 | MYL9 | chr20 | 35177480 | + | 2152 | 1403 | 209 | 1744 | 511 |
ENST00000373622 | RPN2 | chr20 | 35842268 | + | ENST00000279022 | MYL9 | chr20 | 35177480 | + | 1941 | 1192 | 94 | 1533 | 479 |
ENST00000373622 | RPN2 | chr20 | 35842268 | + | ENST00000346786 | MYL9 | chr20 | 35177480 | + | 1941 | 1192 | 94 | 1533 | 479 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000237530 | ENST00000279022 | RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177480 | + | 0.015653351 | 0.9843466 |
ENST00000237530 | ENST00000346786 | RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177480 | + | 0.015653351 | 0.9843466 |
ENST00000373622 | ENST00000279022 | RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177480 | + | 0.015157995 | 0.98484194 |
ENST00000373622 | ENST00000346786 | RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177480 | + | 0.015157995 | 0.98484194 |
Top |
Fusion Genomic Features for RPN2-MYL9 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177479 | + | 7.69E-15 | 1 |
RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177479 | + | 7.69E-15 | 1 |
RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177479 | + | 7.69E-15 | 1 |
RPN2 | chr20 | 35842268 | + | MYL9 | chr20 | 35177479 | + | 7.69E-15 | 1 |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for RPN2-MYL9 |
Go to FGviewer for the breakpoints of chr20:35842268-chr20:35177480 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
. | MYL9 |
FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Myosin regulatory subunit that plays an important role in regulation of both smooth muscle and nonmuscle cell contractile activity via its phosphorylation. Implicated in cytokinesis, receptor capping, and cell locomotion (PubMed:11942626, PubMed:2526655). In myoblasts, may regulate PIEZO1-dependent cortical actomyosin assembly involved in myotube formation (By similarity). {ECO:0000250|UniProtKB:Q9CQ19, ECO:0000269|PubMed:11942626, ECO:0000269|PubMed:2526655}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Tgene | MYL9 | chr20:35842268 | chr20:35177480 | ENST00000279022 | 2 | 4 | 134_169 | 115.33333333333333 | 173.0 | Domain | EF-hand 3 | |
Tgene | MYL9 | chr20:35842268 | chr20:35177480 | ENST00000346786 | 1 | 3 | 134_169 | 61.333333333333336 | 119.0 | Domain | EF-hand 3 | |
Tgene | MYL9 | chr20:35842268 | chr20:35177480 | ENST00000346786 | 1 | 3 | 98_133 | 61.333333333333336 | 119.0 | Domain | EF-hand 2 |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | RPN2 | chr20:35842268 | chr20:35177480 | ENST00000237530 | + | 9 | 17 | 23_540 | 364.0 | 632.0 | Topological domain | Lumenal |
Hgene | RPN2 | chr20:35842268 | chr20:35177480 | ENST00000237530 | + | 9 | 17 | 562_571 | 364.0 | 632.0 | Topological domain | Cytoplasmic |
Hgene | RPN2 | chr20:35842268 | chr20:35177480 | ENST00000237530 | + | 9 | 17 | 593_596 | 364.0 | 632.0 | Topological domain | Lumenal |
Hgene | RPN2 | chr20:35842268 | chr20:35177480 | ENST00000237530 | + | 9 | 17 | 618_631 | 364.0 | 632.0 | Topological domain | Cytoplasmic |
Hgene | RPN2 | chr20:35842268 | chr20:35177480 | ENST00000373622 | + | 8 | 17 | 23_540 | 332.0 | 616.0 | Topological domain | Lumenal |
Hgene | RPN2 | chr20:35842268 | chr20:35177480 | ENST00000373622 | + | 8 | 17 | 562_571 | 332.0 | 616.0 | Topological domain | Cytoplasmic |
Hgene | RPN2 | chr20:35842268 | chr20:35177480 | ENST00000373622 | + | 8 | 17 | 593_596 | 332.0 | 616.0 | Topological domain | Lumenal |
Hgene | RPN2 | chr20:35842268 | chr20:35177480 | ENST00000373622 | + | 8 | 17 | 618_631 | 332.0 | 616.0 | Topological domain | Cytoplasmic |
Hgene | RPN2 | chr20:35842268 | chr20:35177480 | ENST00000237530 | + | 9 | 17 | 541_561 | 364.0 | 632.0 | Transmembrane | Helical |
Hgene | RPN2 | chr20:35842268 | chr20:35177480 | ENST00000237530 | + | 9 | 17 | 572_592 | 364.0 | 632.0 | Transmembrane | Helical |
Hgene | RPN2 | chr20:35842268 | chr20:35177480 | ENST00000237530 | + | 9 | 17 | 597_617 | 364.0 | 632.0 | Transmembrane | Helical |
Hgene | RPN2 | chr20:35842268 | chr20:35177480 | ENST00000373622 | + | 8 | 17 | 541_561 | 332.0 | 616.0 | Transmembrane | Helical |
Hgene | RPN2 | chr20:35842268 | chr20:35177480 | ENST00000373622 | + | 8 | 17 | 572_592 | 332.0 | 616.0 | Transmembrane | Helical |
Hgene | RPN2 | chr20:35842268 | chr20:35177480 | ENST00000373622 | + | 8 | 17 | 597_617 | 332.0 | 616.0 | Transmembrane | Helical |
Tgene | MYL9 | chr20:35842268 | chr20:35177480 | ENST00000279022 | 2 | 4 | 42_53 | 115.33333333333333 | 173.0 | Calcium binding | . | |
Tgene | MYL9 | chr20:35842268 | chr20:35177480 | ENST00000346786 | 1 | 3 | 42_53 | 61.333333333333336 | 119.0 | Calcium binding | . | |
Tgene | MYL9 | chr20:35842268 | chr20:35177480 | ENST00000279022 | 2 | 4 | 29_64 | 115.33333333333333 | 173.0 | Domain | EF-hand 1 | |
Tgene | MYL9 | chr20:35842268 | chr20:35177480 | ENST00000279022 | 2 | 4 | 98_133 | 115.33333333333333 | 173.0 | Domain | EF-hand 2 | |
Tgene | MYL9 | chr20:35842268 | chr20:35177480 | ENST00000346786 | 1 | 3 | 29_64 | 61.333333333333336 | 119.0 | Domain | EF-hand 1 |
Top |
Fusion Gene Sequence for RPN2-MYL9 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>In-frame_ENST00000237530_ENST00000279022_TCGA-66-2793-01A_RPN2_chr20_35842268_+_MYL9_chr20_35177480_length(transcript)=2152nt_BP=1403nt GCGTCCCGGTAGCTCCCGGAATAGGAGCGTTGCGAGACGGTCGGTTCCAAGTGGGCCTGGGCGCGGGGGAGAGGCGGGTCTGTCCTCGGG AACTGCAAGGCCCTGTGAGCGGGAGGACTGGGATCCCGGCCGCGGCTGCTGGAAGCGTCGAAGCTCAGCGGGGCCGCGGACACTGACCTG TGCTTAGAACTCATCCTGGCCCGCAGAGCCTGCCGCGAGTCCCTGGCGTCCCCTGTGGCGGGCTCTTGGAGCCACTTTCCCGAGCGGAAG TCAGCCCGCGGCTCGGACTCCGGCGGGACCTGCTCGGAGGAATGGCGCCGCCGGGTTCAAGCACTGTCTTCCTGTTGGCCCTGACAATCA TAGCCAGCACCTGGGCTCTGACGCCCACTCACTACCTCACCAAGCATGACGTGGAGAGACTAAAAGCCTCGCTGGATCGCCCTTTCACAA ATTTGGAATCTGCCTTCTACTCCATCGTGGGACTCAGCAGCCTTGGTGCTCAGGTGCCAGATGCAAAGAAAGCATGTACCTACATCAGAT CTAACCTTGATCCCAGCAATGTGGATTCCCTCTTCTACGCTGCCCAGGCCAGCCAGGCCCTCTCAGGATGTGAGATCTCTATTTCAAATG AGACCAAAGATCTGCTTCTGGCAGCTGTCAGTGAGGACTCATCTGTTACCCAGATCTACCATGCAGTTGCAGCTCTAAGTGGCTTTGGCC TTCCCTTGGCATCCCAAGAAGCACTCAGTGCCCTTACTGCTCGTCTCAGCAAGGAGGAGACTGTGCTGGCAACAGTCCAGGCTCTGCAGA CAGCATCCCACCTGTCCCAGCAGGCTGACCTGAGGAGCATCGTGGAGGAGATTGAGGACCTTGTTGCTCGCCTGGATGAACTCGGGGGCG TGTATCTCCAGTTTGAAGAAGGACTGGAAACAACAGCGTTATTTGTGGCTGCCACCTACAAGCTCATGGATCATGTGGGGACTGAGCCAT CCATTAAGGAGGATCAGGTCATCCAGCTGATGAACGCGATCTTCAGCAAGAAGAACTTTGAGTCCCTCTCCGAAGCCTTCAGCGTGGCCT CTGCAGCTGCTGTGCTCTCGCATAATCGCTACCACGTGCCAGTTGTGGTTGTGCCTGAGGGCTCTGCTTCCGACACTCATGAACAGGCTA TCTTGCGGTTGCAAGTCACCAATGTTCTGTCTCAGCCTCTGACTCAGGCCACTGTTAAACTAGAACATGCTAAATCTGTTGCTTCCAGAG CCACTGTCCTCCAGAAGACATCCTTCACCCCTGTAGGGGATGTTTTTGAACTAAATTTCATGAACGTCAAATTTTCCAGTGGTTATTATG ACTTCCTTGTCGAAGTTGAAGGTGACAACCGGTATATTGCAAATACCGTAGAGGTTTCATCCATGAGGACCACCTCCGGGAGCTGCTCAC CACCATGGGTGACCGCTTCACAGATGAGGAAGTGGACGAGATGTACCGGGAGGCACCCATTGATAAGAAAGGCAACTTCAACTACGTGGA GTTCACCCGCATCCTCAAACATGGCGCCAAGGATAAAGACGACTAGGCCACCCCAGCCCCCTGACACCCCAGCCCCCGCCAGTCACCCCT CCCCGCACACACCCGTCCATACCAGCTCCCTGCCCATGACCCTCGCTCAGGGATCCCCCTTTGAGGGGTTAGGGTCCCAGTTCCCAGTGG AAGAAACAGGCCAGGAGAAGTGCGTGCCGAGCTGAGGCAGATGTTCCCACAGTGACCCCAGAGCCCTGGGCTATAGTCTCTGACCCCTCC AAGGAAAGACCACCTTCTGGGGACATGGGCTGGAGGGCAGGACCTAGAGGCACCAAGGGAAGGCCCCATTCCGGGGCTGTTCCCCGAGGA GGAAGGGAAGGGGCTCTGTGTGCCCCCCAGGAGGAAGAGGCCCTGAGTCCTGGGATCAGACACCCCTTCACGTGTATCCCCACACAAATG CAAGCTCACCAAGGTCCCCTCTCAGTCCCCTTCCCTACACCCTGACCGGCCACTGCCGCACACCCACCCAGAGCACGCCACCCGCCATGG >In-frame_ENST00000237530_ENST00000279022_TCGA-66-2793-01A_RPN2_chr20_35842268_+_MYL9_chr20_35177480_length(amino acids)=511AA_start in transcript=209_stop in transcript=1744 MPRVPGVPCGGLLEPLSRAEVSPRLGLRRDLLGGMAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIV GLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALS ALTARLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQL MNAIFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQPLTQATVKLEHAKSVASRATVLQKTSFT PVGDVFELNFMNVKFSSGYYDFLVEVEGDNRYIANTVEVSSMRTTSGSCSPPWVTASQMRKWTRCTGRHPLIRKATSTTWSSPASSNMAP -------------------------------------------------------------- >In-frame_ENST00000237530_ENST00000346786_TCGA-66-2793-01A_RPN2_chr20_35842268_+_MYL9_chr20_35177480_length(transcript)=2152nt_BP=1403nt GCGTCCCGGTAGCTCCCGGAATAGGAGCGTTGCGAGACGGTCGGTTCCAAGTGGGCCTGGGCGCGGGGGAGAGGCGGGTCTGTCCTCGGG AACTGCAAGGCCCTGTGAGCGGGAGGACTGGGATCCCGGCCGCGGCTGCTGGAAGCGTCGAAGCTCAGCGGGGCCGCGGACACTGACCTG TGCTTAGAACTCATCCTGGCCCGCAGAGCCTGCCGCGAGTCCCTGGCGTCCCCTGTGGCGGGCTCTTGGAGCCACTTTCCCGAGCGGAAG TCAGCCCGCGGCTCGGACTCCGGCGGGACCTGCTCGGAGGAATGGCGCCGCCGGGTTCAAGCACTGTCTTCCTGTTGGCCCTGACAATCA TAGCCAGCACCTGGGCTCTGACGCCCACTCACTACCTCACCAAGCATGACGTGGAGAGACTAAAAGCCTCGCTGGATCGCCCTTTCACAA ATTTGGAATCTGCCTTCTACTCCATCGTGGGACTCAGCAGCCTTGGTGCTCAGGTGCCAGATGCAAAGAAAGCATGTACCTACATCAGAT CTAACCTTGATCCCAGCAATGTGGATTCCCTCTTCTACGCTGCCCAGGCCAGCCAGGCCCTCTCAGGATGTGAGATCTCTATTTCAAATG AGACCAAAGATCTGCTTCTGGCAGCTGTCAGTGAGGACTCATCTGTTACCCAGATCTACCATGCAGTTGCAGCTCTAAGTGGCTTTGGCC TTCCCTTGGCATCCCAAGAAGCACTCAGTGCCCTTACTGCTCGTCTCAGCAAGGAGGAGACTGTGCTGGCAACAGTCCAGGCTCTGCAGA CAGCATCCCACCTGTCCCAGCAGGCTGACCTGAGGAGCATCGTGGAGGAGATTGAGGACCTTGTTGCTCGCCTGGATGAACTCGGGGGCG TGTATCTCCAGTTTGAAGAAGGACTGGAAACAACAGCGTTATTTGTGGCTGCCACCTACAAGCTCATGGATCATGTGGGGACTGAGCCAT CCATTAAGGAGGATCAGGTCATCCAGCTGATGAACGCGATCTTCAGCAAGAAGAACTTTGAGTCCCTCTCCGAAGCCTTCAGCGTGGCCT CTGCAGCTGCTGTGCTCTCGCATAATCGCTACCACGTGCCAGTTGTGGTTGTGCCTGAGGGCTCTGCTTCCGACACTCATGAACAGGCTA TCTTGCGGTTGCAAGTCACCAATGTTCTGTCTCAGCCTCTGACTCAGGCCACTGTTAAACTAGAACATGCTAAATCTGTTGCTTCCAGAG CCACTGTCCTCCAGAAGACATCCTTCACCCCTGTAGGGGATGTTTTTGAACTAAATTTCATGAACGTCAAATTTTCCAGTGGTTATTATG ACTTCCTTGTCGAAGTTGAAGGTGACAACCGGTATATTGCAAATACCGTAGAGGTTTCATCCATGAGGACCACCTCCGGGAGCTGCTCAC CACCATGGGTGACCGCTTCACAGATGAGGAAGTGGACGAGATGTACCGGGAGGCACCCATTGATAAGAAAGGCAACTTCAACTACGTGGA GTTCACCCGCATCCTCAAACATGGCGCCAAGGATAAAGACGACTAGGCCACCCCAGCCCCCTGACACCCCAGCCCCCGCCAGTCACCCCT CCCCGCACACACCCGTCCATACCAGCTCCCTGCCCATGACCCTCGCTCAGGGATCCCCCTTTGAGGGGTTAGGGTCCCAGTTCCCAGTGG AAGAAACAGGCCAGGAGAAGTGCGTGCCGAGCTGAGGCAGATGTTCCCACAGTGACCCCAGAGCCCTGGGCTATAGTCTCTGACCCCTCC AAGGAAAGACCACCTTCTGGGGACATGGGCTGGAGGGCAGGACCTAGAGGCACCAAGGGAAGGCCCCATTCCGGGGCTGTTCCCCGAGGA GGAAGGGAAGGGGCTCTGTGTGCCCCCCAGGAGGAAGAGGCCCTGAGTCCTGGGATCAGACACCCCTTCACGTGTATCCCCACACAAATG CAAGCTCACCAAGGTCCCCTCTCAGTCCCCTTCCCTACACCCTGACCGGCCACTGCCGCACACCCACCCAGAGCACGCCACCCGCCATGG >In-frame_ENST00000237530_ENST00000346786_TCGA-66-2793-01A_RPN2_chr20_35842268_+_MYL9_chr20_35177480_length(amino acids)=511AA_start in transcript=209_stop in transcript=1744 MPRVPGVPCGGLLEPLSRAEVSPRLGLRRDLLGGMAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIV GLSSLGAQVPDAKKACTYIRSNLDPSNVDSLFYAAQASQALSGCEISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALS ALTARLSKEETVLATVQALQTASHLSQQADLRSIVEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQL MNAIFSKKNFESLSEAFSVASAAAVLSHNRYHVPVVVVPEGSASDTHEQAILRLQVTNVLSQPLTQATVKLEHAKSVASRATVLQKTSFT PVGDVFELNFMNVKFSSGYYDFLVEVEGDNRYIANTVEVSSMRTTSGSCSPPWVTASQMRKWTRCTGRHPLIRKATSTTWSSPASSNMAP -------------------------------------------------------------- >In-frame_ENST00000373622_ENST00000279022_TCGA-66-2793-01A_RPN2_chr20_35842268_+_MYL9_chr20_35177480_length(transcript)=1941nt_BP=1192nt GACTGGGATCCCGGCCGCGGCTGCTGGAAGCGTCGAAGCTCAGCGGGGCCGCGGACACTGACCTGTGCTTAGAACTCATCCTGGCCCGCA GAGCCTGCCGCGAGTCCCTGGCGTCCCCTGTGGCGGGCTCTTGGAGCCACTTTCCCGAGCGGAAGTCAGCCCGCGGCTCGGACTCCGGCG GGACCTGCTCGGAGGAATGGCGCCGCCGGGTTCAAGCACTGTCTTCCTGTTGGCCCTGACAATCATAGCCAGCACCTGGGCTCTGACGCC CACTCACTACCTCACCAAGCATGACGTGGAGAGACTAAAAGCCTCGCTGGATCGCCCTTTCACAAATTTGGAATCTGCCTTCTACTCCAT CGTGGGACTCAGCAGCCTTGGTGCTCAGGTGCCAGATGCAAAGATCTCTATTTCAAATGAGACCAAAGATCTGCTTCTGGCAGCTGTCAG TGAGGACTCATCTGTTACCCAGATCTACCATGCAGTTGCAGCTCTAAGTGGCTTTGGCCTTCCCTTGGCATCCCAAGAAGCACTCAGTGC CCTTACTGCTCGTCTCAGCAAGGAGGAGACTGTGCTGGCAACAGTCCAGGCTCTGCAGACAGCATCCCACCTGTCCCAGCAGGCTGACCT GAGGAGCATCGTGGAGGAGATTGAGGACCTTGTTGCTCGCCTGGATGAACTCGGGGGCGTGTATCTCCAGTTTGAAGAAGGACTGGAAAC AACAGCGTTATTTGTGGCTGCCACCTACAAGCTCATGGATCATGTGGGGACTGAGCCATCCATTAAGGAGGATCAGGTCATCCAGCTGAT GAACGCGATCTTCAGCAAGAAGAACTTTGAGTCCCTCTCCGAAGCCTTCAGCGTGGCCTCTGCAGCTGCTGTGCTCTCGCATAATCGCTA CCACGTGCCAGTTGTGGTTGTGCCTGAGGGCTCTGCTTCCGACACTCATGAACAGGCTATCTTGCGGTTGCAAGTCACCAATGTTCTGTC TCAGCCTCTGACTCAGGCCACTGTTAAACTAGAACATGCTAAATCTGTTGCTTCCAGAGCCACTGTCCTCCAGAAGACATCCTTCACCCC TGTAGGGGATGTTTTTGAACTAAATTTCATGAACGTCAAATTTTCCAGTGGTTATTATGACTTCCTTGTCGAAGTTGAAGGTGACAACCG GTATATTGCAAATACCGTAGAGGTTTCATCCATGAGGACCACCTCCGGGAGCTGCTCACCACCATGGGTGACCGCTTCACAGATGAGGAA GTGGACGAGATGTACCGGGAGGCACCCATTGATAAGAAAGGCAACTTCAACTACGTGGAGTTCACCCGCATCCTCAAACATGGCGCCAAG GATAAAGACGACTAGGCCACCCCAGCCCCCTGACACCCCAGCCCCCGCCAGTCACCCCTCCCCGCACACACCCGTCCATACCAGCTCCCT GCCCATGACCCTCGCTCAGGGATCCCCCTTTGAGGGGTTAGGGTCCCAGTTCCCAGTGGAAGAAACAGGCCAGGAGAAGTGCGTGCCGAG CTGAGGCAGATGTTCCCACAGTGACCCCAGAGCCCTGGGCTATAGTCTCTGACCCCTCCAAGGAAAGACCACCTTCTGGGGACATGGGCT GGAGGGCAGGACCTAGAGGCACCAAGGGAAGGCCCCATTCCGGGGCTGTTCCCCGAGGAGGAAGGGAAGGGGCTCTGTGTGCCCCCCAGG AGGAAGAGGCCCTGAGTCCTGGGATCAGACACCCCTTCACGTGTATCCCCACACAAATGCAAGCTCACCAAGGTCCCCTCTCAGTCCCCT TCCCTACACCCTGACCGGCCACTGCCGCACACCCACCCAGAGCACGCCACCCGCCATGGGAGTGTGCTCAGGAGTCGCGGGCAGCGTGGA >In-frame_ENST00000373622_ENST00000279022_TCGA-66-2793-01A_RPN2_chr20_35842268_+_MYL9_chr20_35177480_length(amino acids)=479AA_start in transcript=94_stop in transcript=1533 MPRVPGVPCGGLLEPLSRAEVSPRLGLRRDLLGGMAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIV GLSSLGAQVPDAKISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLR SIVEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFESLSEAFSVASAAAVLSHNRYH VPVVVVPEGSASDTHEQAILRLQVTNVLSQPLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDNRY IANTVEVSSMRTTSGSCSPPWVTASQMRKWTRCTGRHPLIRKATSTTWSSPASSNMAPRIKTTRPPQPPDTPAPASHPSPHTPVHTSSLP -------------------------------------------------------------- >In-frame_ENST00000373622_ENST00000346786_TCGA-66-2793-01A_RPN2_chr20_35842268_+_MYL9_chr20_35177480_length(transcript)=1941nt_BP=1192nt GACTGGGATCCCGGCCGCGGCTGCTGGAAGCGTCGAAGCTCAGCGGGGCCGCGGACACTGACCTGTGCTTAGAACTCATCCTGGCCCGCA GAGCCTGCCGCGAGTCCCTGGCGTCCCCTGTGGCGGGCTCTTGGAGCCACTTTCCCGAGCGGAAGTCAGCCCGCGGCTCGGACTCCGGCG GGACCTGCTCGGAGGAATGGCGCCGCCGGGTTCAAGCACTGTCTTCCTGTTGGCCCTGACAATCATAGCCAGCACCTGGGCTCTGACGCC CACTCACTACCTCACCAAGCATGACGTGGAGAGACTAAAAGCCTCGCTGGATCGCCCTTTCACAAATTTGGAATCTGCCTTCTACTCCAT CGTGGGACTCAGCAGCCTTGGTGCTCAGGTGCCAGATGCAAAGATCTCTATTTCAAATGAGACCAAAGATCTGCTTCTGGCAGCTGTCAG TGAGGACTCATCTGTTACCCAGATCTACCATGCAGTTGCAGCTCTAAGTGGCTTTGGCCTTCCCTTGGCATCCCAAGAAGCACTCAGTGC CCTTACTGCTCGTCTCAGCAAGGAGGAGACTGTGCTGGCAACAGTCCAGGCTCTGCAGACAGCATCCCACCTGTCCCAGCAGGCTGACCT GAGGAGCATCGTGGAGGAGATTGAGGACCTTGTTGCTCGCCTGGATGAACTCGGGGGCGTGTATCTCCAGTTTGAAGAAGGACTGGAAAC AACAGCGTTATTTGTGGCTGCCACCTACAAGCTCATGGATCATGTGGGGACTGAGCCATCCATTAAGGAGGATCAGGTCATCCAGCTGAT GAACGCGATCTTCAGCAAGAAGAACTTTGAGTCCCTCTCCGAAGCCTTCAGCGTGGCCTCTGCAGCTGCTGTGCTCTCGCATAATCGCTA CCACGTGCCAGTTGTGGTTGTGCCTGAGGGCTCTGCTTCCGACACTCATGAACAGGCTATCTTGCGGTTGCAAGTCACCAATGTTCTGTC TCAGCCTCTGACTCAGGCCACTGTTAAACTAGAACATGCTAAATCTGTTGCTTCCAGAGCCACTGTCCTCCAGAAGACATCCTTCACCCC TGTAGGGGATGTTTTTGAACTAAATTTCATGAACGTCAAATTTTCCAGTGGTTATTATGACTTCCTTGTCGAAGTTGAAGGTGACAACCG GTATATTGCAAATACCGTAGAGGTTTCATCCATGAGGACCACCTCCGGGAGCTGCTCACCACCATGGGTGACCGCTTCACAGATGAGGAA GTGGACGAGATGTACCGGGAGGCACCCATTGATAAGAAAGGCAACTTCAACTACGTGGAGTTCACCCGCATCCTCAAACATGGCGCCAAG GATAAAGACGACTAGGCCACCCCAGCCCCCTGACACCCCAGCCCCCGCCAGTCACCCCTCCCCGCACACACCCGTCCATACCAGCTCCCT GCCCATGACCCTCGCTCAGGGATCCCCCTTTGAGGGGTTAGGGTCCCAGTTCCCAGTGGAAGAAACAGGCCAGGAGAAGTGCGTGCCGAG CTGAGGCAGATGTTCCCACAGTGACCCCAGAGCCCTGGGCTATAGTCTCTGACCCCTCCAAGGAAAGACCACCTTCTGGGGACATGGGCT GGAGGGCAGGACCTAGAGGCACCAAGGGAAGGCCCCATTCCGGGGCTGTTCCCCGAGGAGGAAGGGAAGGGGCTCTGTGTGCCCCCCAGG AGGAAGAGGCCCTGAGTCCTGGGATCAGACACCCCTTCACGTGTATCCCCACACAAATGCAAGCTCACCAAGGTCCCCTCTCAGTCCCCT TCCCTACACCCTGACCGGCCACTGCCGCACACCCACCCAGAGCACGCCACCCGCCATGGGAGTGTGCTCAGGAGTCGCGGGCAGCGTGGA >In-frame_ENST00000373622_ENST00000346786_TCGA-66-2793-01A_RPN2_chr20_35842268_+_MYL9_chr20_35177480_length(amino acids)=479AA_start in transcript=94_stop in transcript=1533 MPRVPGVPCGGLLEPLSRAEVSPRLGLRRDLLGGMAPPGSSTVFLLALTIIASTWALTPTHYLTKHDVERLKASLDRPFTNLESAFYSIV GLSSLGAQVPDAKISISNETKDLLLAAVSEDSSVTQIYHAVAALSGFGLPLASQEALSALTARLSKEETVLATVQALQTASHLSQQADLR SIVEEIEDLVARLDELGGVYLQFEEGLETTALFVAATYKLMDHVGTEPSIKEDQVIQLMNAIFSKKNFESLSEAFSVASAAAVLSHNRYH VPVVVVPEGSASDTHEQAILRLQVTNVLSQPLTQATVKLEHAKSVASRATVLQKTSFTPVGDVFELNFMNVKFSSGYYDFLVEVEGDNRY IANTVEVSSMRTTSGSCSPPWVTASQMRKWTRCTGRHPLIRKATSTTWSSPASSNMAPRIKTTRPPQPPDTPAPASHPSPHTPVHTSSLP -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for RPN2-MYL9 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for RPN2-MYL9 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for RPN2-MYL9 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | RPN2 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Hgene | RPN2 | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
Tgene | MYL9 | C0006114 | Cerebral Edema | 1 | CTD_human |
Tgene | MYL9 | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
Tgene | MYL9 | C0042373 | Vascular Diseases | 1 | CTD_human |
Tgene | MYL9 | C0472387 | Vasogenic Cerebral Edema | 1 | CTD_human |
Tgene | MYL9 | C0472388 | Cytotoxic Cerebral Edema | 1 | CTD_human |
Tgene | MYL9 | C0750969 | Vasogenic Brain Edema | 1 | CTD_human |
Tgene | MYL9 | C0750970 | Cytotoxic Brain Edema | 1 | CTD_human |
Tgene | MYL9 | C1527311 | Brain Edema | 1 | CTD_human |